Mitsuo Nagasaka

Toyoake, 4701192, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.

Journal: Cancers

Published: May 21, 2026

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis.

Journal: Oncology

Published: January 21, 2026

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.

Efficacy of Second-line Lenvatinib for Hepatocellular Carcinoma After Early Progression on Atezolizumab-Bevacizumab.

Journal: Anticancer research

Published: December 16, 2025

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

The Central Role of Liver Function at Treatment Initiation and Its Preservation at Progression for Post-Progression Survival After Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma.

Journal: Biomedicines

Published: December 14, 2025

Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Biomarker-Based Responder Selection and Early Prediction of Treatment Response in Hepatocellular Carcinoma: Dynamic Changes in Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin During Atezolizumab Plus Bevacizumab Therapy.

Journal: Cancers

Published: October 26, 2025

Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Clinical Outcomes of Reduced-Dose Cabozantinib as Third- or Later-Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real-World Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 01, 2025

Amber-red color imaging makes the dissection line more evident during gastric endoscopic submucosal dissection.

Amber-red color imaging makes the dissection line more evident during gastric endoscopic submucosal dissection.

Journal: Endoscopy international open

Published: March 08, 2025

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Journal: Current oncology (Toronto, Ont.)

Published: September 01, 2024

Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma.

Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma.

Journal: Current oncology (Toronto, Ont.)

Published: June 26, 2024

Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.

Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.

Journal: Anticancer research

Published: July 30, 2023

A stag beetle knife can achieve stabler and safer endoscopic submucosal dissection in the esophagus.

A stag beetle knife can achieve stabler and safer endoscopic submucosal dissection in the esophagus.

Journal: Endoscopy international open

Published: July 27, 2023

Large Inflammatory Myofibroblastic Tumor of the Esophagus: A Case Report and Literature Review.

Large Inflammatory Myofibroblastic Tumor of the Esophagus: A Case Report and Literature Review.

Journal: Internal medicine (Tokyo, Japan)

Published: April 21, 2023

Showing 1-12 of 82

Last Updated: 09/26/2026